Warpaint London PLC Announces Interim Results

Warpaint London reported H1 2026 revenue of £40.5m, down 17.8% year over year, while adjusted EBITDA fell 36.4% to £6.8m and adjusted EPS declined 46.6% to 4.5p amid challenging trading conditions, order timing and non-recurring prior-year sales. Gross margin improved 230bps to 47.3%, including roughly 150bps from discounted Barry M inventory acquired in February, while operating cash flow rose 80.9% to £7.4m. The debt-free group increased cash to £20.7m and raised its interim dividend 6.25% to 4.25p per share.

Analysis

The key valuation issue is not the reported gross-margin expansion but its durability. A material portion appears inventory-accounting related and should unwind as acquired stock is sold, leaving the market to judge whether re-sourcing and product mix can offset that normalization; absent organic revenue stabilization, operating leverage is negative and EBITDA-margin expectations for FY26-FY27 are vulnerable. The cash build provides downside protection, but a rising dividend during a profit reset could be read as capital-allocation signaling rather than evidence of earnings growth.

Barry M creates a potentially attractive distribution and procurement platform if Warpaint can extend the brand through its existing value-retail channels without cannibalizing W7 or Technic. The more likely near-term risk is that retailers rationalize shelf space in a weak discretionary environment, making acquired-brand revenue additive only at the cost of promotional intensity. Larger branded beauty peers with stronger retailer leverage may absorb demand volatility better, while W7L's AIM liquidity and small free float can amplify any guidance revision.

Consensus may over-penalize the top-line decline if H2 customer order timing reverses and the acquired brand's run-rate is demonstrably incremental. But this is an earnings-quality debate, not yet a clean growth reacceleration: the thesis turns constructive only if underlying sales excluding acquisition and prior-period nonrecurring items stabilize while gross margin remains above the pre-acquisition run rate.

Key Decisions for Investors

• Remain neutral on W7L through the next trading update; upgrade to a tactical long only if management discloses organic sales stabilization and confirms that post-acquisition gross margin can hold above roughly 45% after discounted inventory is exhausted. A 1-3 month rerating catalyst would be evidence of H2 order conversion rather than further dividend actions.
• For existing W7L holders, retain exposure only with a defined thesis stop at a FY26 EBITDA-guidance cut or evidence that Barry M sales are substituting for legacy-brand demand. The principal downside is multiple compression from an earnings-quality reset, exacerbated by AIM liquidity.
• Monitor REV.L as the closest listed UK value-beauty read-through: sustained promotional activity, retailer delistings, or weak sell-through at REV would increase the probability that W7L's revenue weakness is demand-led rather than timing-led. This is an alert, not a pair recommendation, given materially different balance-sheet and execution risk.
• Do not treat the increased payout as a standalone buy signal. Reassess capital returns after full-year working-capital data: a reversal in operating cash conversion or renewed inventory build would falsify the argument that the balance sheet can simultaneously support integration, dividend growth, and further acquisitions.